A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Healthy Overweight/Obese Subjects and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2014
At a glance
- Drugs MK 5823 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck & Co
- 25 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Jul 2012 Planned End Date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.